These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22266038)

  • 1. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.
    Cumming JG; Tucker H; Oldfield J; Fielding C; Highton A; Faull A; Wild M; Brown D; Wells S; Shaw J
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1655-9. PubMed ID: 22266038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
    Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
    Curr Top Med Chem; 2008; 8(13):1140-51. PubMed ID: 18782009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides.
    Cumming JG; Cooper AE; Grime K; Logan CJ; McLaughlin S; Oldfield J; Shaw JS; Tucker H; Winter J; Whittaker D
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5012-5. PubMed ID: 16154744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc.
    Price DA; Armour D; de Groot M; Leishman D; Napier C; Perros M; Stammen BL; Wood A
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4633-7. PubMed ID: 16782336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate.
    Gerlag DM; Hollis S; Layton M; Vencovský J; Szekanecz Z; Braddock M; Tak PP;
    Arthritis Rheum; 2010 Nov; 62(11):3154-60. PubMed ID: 20662070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
    Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
    J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and evaluation of an in silico model for hERG binding.
    Song M; Clark M
    J Chem Inf Model; 2006; 46(1):392-400. PubMed ID: 16426073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design and discovery of novel amide CCR5 antagonists.
    Pryde DC; Corless M; Fenwick DR; Mason HJ; Stammen BC; Stephenson PT; Ellis D; Bachelor D; Gordon D; Barber CG; Wood A; Middleton DS; Blakemore DC; Parsons GC; Eastwood R; Platts MY; Statham K; Paradowski KA; Burt C; Klute W
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1084-8. PubMed ID: 19167884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities.
    Sakauchi N; Kohara Y; Sato A; Suzaki T; Imai Y; Okabe Y; Imai S; Saikawa R; Nagabukuro H; Kuno H; Fujita H; Kamo I; Yoshida M
    J Med Chem; 2016 Apr; 59(7):2989-3002. PubMed ID: 26954848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
    Sato N; Ando M; Ishikawa S; Jitsuoka M; Nagai K; Takahashi H; Sakuraba A; Tsuge H; Kitazawa H; Iwaasa H; Mashiko S; Gomori A; Moriya R; Fujino N; Ohe T; Ishihara A; Kanatani A; Fukami T
    J Med Chem; 2009 May; 52(10):3385-96. PubMed ID: 19459652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists.
    Nirogi R; Shinde A; Daulatabad A; Kambhampati R; Gudla P; Shaik M; Gampa M; Balasubramaniam S; Gangadasari P; Reballi V; Badange R; Bojja K; Subramanian R; Bhyrapuneni G; Muddana N; Jayarajan P
    J Med Chem; 2012 Nov; 55(21):9255-69. PubMed ID: 23006002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR.
    Johnson SR; Yue H; Conder ML; Shi H; Doweyko AM; Lloyd J; Levesque P
    Bioorg Med Chem; 2007 Sep; 15(18):6182-92. PubMed ID: 17596950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring chemical substructures essential for HERG k(+) channel blockade by synthesis and biological evaluation of dofetilide analogues.
    ; Guo D; Klaasse E; de Vries H; Brussee J; Nalos L; Rook MB; Vos MA; van der Heyden MA; Ijzerman AP
    ChemMedChem; 2009 Oct; 4(10):1722-32. PubMed ID: 19725081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
    Schmidtke P; Ciantar M; Theret I; Ducrot P
    J Chem Inf Model; 2014 Aug; 54(8):2320-33. PubMed ID: 25000969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel and orally active NR2B-selective N-methyl-D-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity.
    Kawai M; Nakamura H; Sakurada I; Shimokawa H; Tanaka H; Matsumizu M; Ando K; Hattori K; Ohta A; Nukui S; Omura A; Kawamura M
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5533-6. PubMed ID: 17768047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel N-aryl piperazine CXCR4 antagonists.
    Zhao H; Prosser AR; Liotta DC; Wilson LJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4950-4955. PubMed ID: 25935642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The design and synthesis of potent and cell-active allosteric dual Akt 1 and 2 inhibitors devoid of hERG activity.
    Siu T; Li Y; Nagasawa J; Liang J; Tehrani L; Chua P; Jones RE; Defeo-Jones D; Barnett SF; Robinson RG
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4191-4. PubMed ID: 18550373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
    Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships.
    Shamovsky I; Connolly S; David L; Ivanova S; Nordén B; Springthorpe B; Urbahns K
    J Med Chem; 2008 Mar; 51(5):1162-78. PubMed ID: 18257512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide.
    Carvalho JF; Louvel J; Doornbos ML; Klaasse E; Yu Z; Brussee J; IJzerman AP
    J Med Chem; 2013 Apr; 56(7):2828-40. PubMed ID: 23473309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.